MEK2 Research is excited to announce a new partnership with ADViRNA to advance experimental siRNA- and ASO-based (antisense oligonucleotide) therapeutic strategies aimed at silencing or correcting the expression of the mutant MEK2 allele. As part of this collaboration, ADViRNA will design a panel of oligonucleotides specifically targeting the disease-causing SNP.
The project will be supported by ADViRNA’s experienced scientific team:
- Alexey Wolfson, PhD, MBA — Chief Executive Officer & Chief Scientific Officer
- Sean McCauley, PhD — Lead Scientist
- Kyle Foster, PhD — Scientific Project Manager
- Nick Rice, PhD — Scientist, Research and Development
- Hannah McCauley — Senior Research Associate, Director of Corporate Operations
- Sarah Goudreau — Senior Research Associate



